90Y-DOTA-FF-21101 is a chimeric monoclonal anti-P-Cadherin (CDH3) labeled with Yttrium-90 via the chelator DOTA. 90Y-DOTA-FF-21101 is targeting CDH3 receptors which are expressed in a variety of tumors and play a role in cell adhesion, motility, invasion, and proliferation. As such the number of indications of interest can be quite large, including lung, pancreatic and colon cancers.
A clinical safety and tolerability study (Phase I) in subjects receive 111In-FF-21101 for Dosimetry and 90Y-FF-21101 for treatment of advanced solid tumors has been initiated in 2016. This study is expected to be completed by end of 2021 regarding primary data. A Phase I study was also initiated in Japan in April 2020 . Indications include ovarian, biliary tract and head-and-neck solid tumors.
Leading Emitter: beta electrons (β–)